SRTAW - Strata Critical Me... Stock Analysis | Stock Taper
Logo
Strata Critical Medical, Inc.

SRTAW

Strata Critical Medical, Inc. NASDAQ
$0.06 50.00% (+0.02)

Market Cap $2.83 M
52w High $0.06
52w Low $0.04
P/E 0
Volume 7.05K
Outstanding Shares 70.76M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $49.3M $17.24M $57.42M 116.47% $-0.04 $-9.24M
Q2-2025 $70.8M $22.69M $-3.74M -5.29% $-0.05 $-3.18M
Q1-2025 $54.31M $19.56M $-3.49M -6.43% $-0.04 $-5.89M
Q4-2024 $54.36M $20.96M $-9.79M -18.02% $-0.12 $-6.84M
Q3-2024 $74.88M $23.37M $-1.95M -2.61% $-0.03 $-2.26M

What's going well?

The company reported a big profit this quarter, thanks to a one-time gain from selling part of the business. Operating expenses were cut, and there is no debt burden.

What's concerning?

Sales dropped sharply, gross profit fell, and the core business is still losing money. The reported profit is not from actual operations, so the underlying business remains weak.

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $75.92M $335.08M $52.08M $283M
Q2-2025 $113.42M $257.92M $34.82M $223.1M
Q1-2025 $120.01M $250.55M $30.82M $219.73M
Q4-2024 $127.14M $256.68M $34.74M $221.94M
Q3-2024 $136.34M $282.94M $49.45M $233.5M

What's financially strong about this company?

The company has very low debt, lots of equity, and can easily pay its bills. Book value and equity are growing, showing financial strength.

What are the financial risks or weaknesses?

Cash and investments fell sharply this quarter, and a large portion of assets is now goodwill and intangibles, which could be risky if acquisitions disappoint.

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-9.66M $-31.84M $2.4M $-7.24M $-37.3M $-34.97M
Q2-2025 $-3.74M $-4.21M $28.68M $14K $24.63M $-6.94M
Q1-2025 $-3.49M $-4.55M $20.41M $60K $16.04M $-7.7M
Q4-2024 $-9.79M $13K $3.98M $-5.64M $-1.76M $-5.03M
Q3-2024 $-1.95M $6.36M $-12.65M $-731K $-6.96M $-3.56M

What's strong about this company's cash flow?

Working capital movements helped cash flow this quarter, and there is still $23 million in cash left. No debt means no interest burden.

What are the cash flow concerns?

Operating and free cash flow losses have ballooned, and the company is burning through its cash reserves quickly. Without new funding, cash could run out in less than a year.

Q3 2025 Earnings Call Summary

Read Call Summary

5-Year Trend Analysis

A comprehensive look at Strata Critical Medical, Inc.'s financial evolution and strategic trajectory over the past five years.

+ Strengths

SRTAW’s main strengths are its rapid revenue growth, steadily improving margins, and conservative balance sheet with low debt and a net cash position. The company has shown it can scale its top line and enhance gross profitability while gradually bringing operating costs under better control. Prior R&D investment and recent capacity expansion suggest management is willing to invest for growth, not just cut its way to better numbers.

! Risks

The key risks center on persistent losses, negative free cash flow, and steadily worsening retained earnings, which collectively show that the business model has not yet proven financially self-sustaining. Liquidity, while still solid, is trending downward as cash is consumed, and the company remains reliant on external capital to fund operations and investments. There is also uncertainty around the durability of its competitive position and the long-term impact of reduced R&D spending on innovation.

Outlook

If current trends continue—revenue growing, margins improving, and operating cash burn shrinking—the company could move meaningfully closer to breakeven over the next few years, which would ease pressure on the balance sheet and reduce funding risk. However, the path is not guaranteed: any slowdown in growth, need to reincrease spending to defend its position, or difficulty raising new capital could delay or derail that trajectory. The outlook is thus balanced between promising operational momentum and the ongoing challenge of turning a high-growth story into a sustainably profitable one.